This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Lipoprotein Research Stockholm Ab, The Kitasato Institute. Active years: 2026.
Company Filing History:
1 out of 1 
1 out of 102 Years Active: 2026
Title: Camilla Pramfalk: Innovator in Pharmaceutical Research
Introduction
Camilla Pramfalk is a notable inventor based in Stockholm, Sweden. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological functions. Her work has implications for the treatment of various diseases and disorders.
Latest Patents
Camilla Pramfalk holds a patent for a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. This low-molecular weight compound is designed to inhibit the functions of PCSK9, which plays a crucial role in cholesterol metabolism. The patent details a PCSK9 inhibitor that includes a compound represented by a specific formula, along with its pharmaceutically acceptable salts or solvates. This invention is aimed at preventing or treating symptoms, diseases, or disorders related to PCSK9 functions.
Career Highlights
Throughout her career, Camilla has worked with esteemed organizations such as The Kitasato Institute and Lipoprotein Research Stockholm AB. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Camilla Pramfalk is a pioneering inventor whose work in developing PCSK9 inhibitors showcases her commitment to advancing pharmaceutical research. Her contributions are vital for the ongoing efforts to improve health outcomes related to cholesterol management.